Biotest AG (XTER:BIO3) Institutional Ownership : 0.20% (As of Dec. 15, 2024)

View and export this data going back to 1987. Start your Free Trial

What is Biotest AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biotest AG's institutional ownership is 0.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biotest AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biotest AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Biotest AG Institutional Ownership Historical Data

The historical data trend for Biotest AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Institutional Ownership Chart

Biotest AG Historical Data

The historical data trend for Biotest AG can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	0.38	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20

Biotest AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biotest AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (XTER:BIO3) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0N70:UK BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Executives

Dr. Katrin Bernöster	Vice President Corp. Project + Portfolio Management
Dr. Martin Reinecke	Senior Vice President plasma alliances and proteine supply
Stephan Fleck	Vice President Corporate Controlling
Dr. Jörg Schüttrumpf	VP Corp. Research &Development
Michael Moritz	VP CC Materials & Facility Management

Biotest AG Headlines

No Headlines